
FDA Approves Moderna's mRNA Flu Vaccine for US Adults 50+
The FDA has approved Moderna's mRNA-based influenza vaccine, mFLUSIVA, for US adults aged 50 and over, marking the first mRNA flu vaccine authorized in the US, leveraging technology from the Covid-19 pandemic.


















